Top

Published in:

01-10-2017 | Literatur kommentiert

Können 12- statt 4‑wöchentliche Zoledronsäuregaben skelettale Ereignisse bei Patienten mit Knochenmetastasen reduzieren?

Author: Prof. Dr. med. Dirk Rades

Published in: Strahlentherapie und Onkologie | Issue 10/2017

Auszug

In einer randomisierten Open-label-Studie wurde die Nichtunterlegenheit der Gabe von 4 mg Zoledronsäure alle 12 Wochen für 2 Jahre (Arm A) gegenüber der Standardapplikation von 4 mg Zoledronsäure alle 4 Wochen für 2 Jahre (Arm B) hinsichtlich der Rate an skelettalen Ereignissen (Frakturen, Rückenmarkkompression, Strahlentherapie oder Operation ossärer Metastasen) binnen 2 Jahren überprüft. …

Himelstein AL, Foster JC, Khatcheressian JL et al (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases. A randomized clinical trial. JAMA 317:48–58CrossRefPubMedPubMedCentral

Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468CrossRefPubMed

Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882CrossRefPubMed

Rades D, Lange M, Veninga T et al (2011) Final results of a prospective study comparing the local control of short-course and long-course radiotherapy for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 79:524–530CrossRefPubMed

Rades D, Hakim SG, Bajrovic A et al (2012) Impact of zoledronic acid on control of metastatic spinal cord compression. Strahlenther Onkol 188:910–916CrossRefPubMed

Smith MR, Halabi S, Ryan CJ et al (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143–1150CrossRefPubMedPubMedCentral

Stopeck AT, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139CrossRefPubMed

Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822CrossRefPubMedPubMedCentral

Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125–1132CrossRefPubMed

10.

Van Poznak CH, Temin S, Yee GC et al (2011) American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221–1227CrossRefPubMed

11.

Prevention of symptomatic skeletal events with denosumab administered every 4 weeks vs every 12 weeks. https://clinicaltrials.gov/ct2/show/NCT02051218?term=denosumab+metastasic&rank=2. Accessed July 19, 2016.

Title: Können 12- statt 4‑wöchentliche Zoledronsäuregaben skelettale Ereignisse bei Patienten mit Knochenmetastasen reduzieren?
Author: Prof. Dr. med. Dirk Rades
Publication date: 01-10-2017
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 10/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-017-1191-0

At a glance: The STEP trials

Springer Medicine

Können 12- statt 4‑wöchentliche Zoledronsäuregaben skelettale Ereignisse bei Patienten mit Knochenmetastasen reduzieren?

Auszug

At a glance: The STEP trials

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 10/2017

Erratum to: An IGRT margin concept for pelvic lymph nodes in high-risk prostate cancer

21st Annual SASRO Meeting

Motion monitoring during a course of lung radiotherapy with anchored electromagnetic transponders

Planning benchmark study for SBRT of early stage NSCLC

Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosis

An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging